<div id="readability-page-1"><p>Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.14, Zacks reports. Swedish Orphan Biovitrum had a negative net margin of 0.97% and a positive return on equity of 13.66%. The firm had revenue of $846.23 million for the quarter, compared to analyst estimates of $879.40 million.</p><h2>Swedish Orphan Biovitrum Stock Performance</h2><p>Shares of OTCMKTS BIOVF remained flat at $37.00 during midday trading on Friday. 1 shares of the stock were exchanged, compared to its average volume of 1. The stock's 50-day simple moving average is $35.96 and its 200 day simple moving average is $33.07. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.02 and a quick ratio of 0.69. The stock has a market capitalization of $13.17 billion, a P/E ratio of -528.57 and a beta of 0.37. Swedish Orphan Biovitrum has a 1-year low of $25.80 and a 1-year high of $37.00. </p><h2>Analysts Set New Price Targets</h2><p>Separately, Deutsche Bank Aktiengesellschaft raised Swedish Orphan Biovitrum from a &#34;sell&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 3rd. One equities research analyst  has rated the stock with a Buy rating,  According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34;.</p><p><b>View Our Latest Stock Analysis on BIOVF</b></p><h2>About Swedish Orphan Biovitrum</h2> (Get Free Report)<p>Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi's strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.  </p><p>The company's marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.</p><h2>See Also</h2><ul><li>Five stocks we like better than Swedish Orphan Biovitrum</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Your Bank Account Is No Longer Safe</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Wall Street’s New Sports Prediction Trade</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPUJJT1ZG?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPUJJT1ZG"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Swedish Orphan Biovitrum Right Now?</h2><p>Before you consider Swedish Orphan Biovitrum, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Swedish Orphan Biovitrum wasn't on the list.</p><p>While Swedish Orphan Biovitrum currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Swedish Orphan Biovitrum (OTCMKTS:BIOVF) reported earnings of $0.60 per share, surpassing estimates of $0.46 by $0.14. The company generated revenue of $846.23 million, below the expected $879.40 million. It has a positive return on equity of 13.66% and a negative net margin of 0.97%. The stock remained flat at $37.00, with a market cap of $13.17 billion. Deutsche Bank upgraded the stock from "sell" to "buy," and it currently holds a consensus rating of "buy" among analysts.</p>

Market Beat

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Direxion S&P Biotech Bear 3X

Vitro Biopharma

ALPS Medical Breakthrough

SPDR S&P Health Equip

Orphazyme A/S Unsponsored ADR

iShares US Pharma

VG Health

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

ABVC BioPharma

iShares US Medical Devices

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Posts Earnings Results, Beats Estimates By $0.14 EPS